Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Steyr – page 34

449 clinical trials in Steyr, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Steyr at a glance
449
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

449 trials in Steyr

Open in trial search

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Follicular lymphoma+2

Not recruiting

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study Comparing MK-7684A with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effects of Romosozumab and Bisphosphonates in Children and Adolescents with Osteogenesis Imperfecta

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Calcium
  • Sponsor:Amgen Inc.

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Study on Ropeginterferon Alfa-2b for Patients with Essential Thrombocythemia Intolerant or Refractory to Other Treatments

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ropeginterferon ALFA-2B
  • Sponsor:Aop Orphan Pharmaceuticals GmbH

Pancreatic carcinoma+3

Not recruiting

Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Brigimadlin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Steyr

What the registry says about research in the country

01 Oncology - Blood Cancers

Innovative research focusing on multiple myeloma treatment approaches, including maintenance therapy post stem-cell transplantation and comparing different administration methods for targeted therapies. Studies also investigate new treatments for Hodgkin Lymphoma with emphasis on reducing toxicity while maintaining efficacy.

  • Multiple Myeloma Treatments
  • Hodgkin Lymphoma Therapy
  • Stem Cell Transplantation

Advanced clinical research evaluating novel drug combinations and administration routes to improve patient outcomes.

02 Breast Cancer Research

Comprehensive studies examining treatments for ER-positive, HER2-negative breast cancer, including both early-stage and advanced disease. Research focuses on novel therapeutic agents and extended treatment strategies to prevent recurrence.

  • Early Breast Cancer Treatment
  • Advanced Breast Cancer Therapy
  • Endocrine Therapy Innovation

Trials aim to improve current treatment standards and evaluate new therapeutic options for breast cancer patients.

03 Pain Management Studies

Extensive research into chronic pain conditions, including diabetic polyneuropathy, post-operative neuropathy, and chronic back pain. Studies evaluate new treatment approaches for various types of neuropathic and musculoskeletal pain.

  • Neuropathic Pain Treatment
  • Chronic Back Pain Management
  • Post-operative Pain Control

Investigations focus on developing effective add-on treatments for chronic pain conditions to improve patient quality of life.

04 Pancreatic Cancer Research

Advanced studies in metastatic pancreatic ductal adenocarcinoma, evaluating novel combination therapies to improve survival rates. Research focuses on comparing standard treatments with new therapeutic approaches.

  • Metastatic Disease Treatment
  • Combination Therapy Assessment
  • Survival Rate Improvement

Clinical trials aim to enhance treatment outcomes for patients with advanced pancreatic cancer.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.